Τίτλος:
Ibrutinib-related atrial fibrillation: therapeutic challenges
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Ibrutinib is a drug used in several lymphohyperplastic diseases. Its use is associated with an increased risk of atrial fibrillation. New-onset atrial fibrillation in this setting is a true challenge as several antiarrhythmic drugs are not indicated and long-term anticoagulation has several limitations. Herein, we describe our experience in treating a 55-year-old patient receiving ibrutinib who presented with new-onset atrial fibrillation and borderline arterial pressure. Since first-line therapies, electrical cardioversion and ablation, could not be performed, rhythm control with intravenous administration of amiodarone was attempted and led to prompt sinus rhythm restoration. We discuss the therapeutic challenges related to sinus rhythm restoration and anticoagulation in this group of atrial fibrillation patients. © The Author(s) 2018.
Συγγραφείς:
Kapelios, C.J.
Bonou, M.S.
Diamantopoulos, P.
Angelopoulou, M.K.
Masoura, C.
Barbetseas, J.
Viniou, N.-A.
Περιοδικό:
Journal of Oncology Pharmacy Practice
Εκδότης:
SAGE Publications Ltd
Λέξεις-κλειδιά:
amiodarone; cyclophosphamide; cyclophosphamide plus doxorubicin plus prednisolone plus rituximab plus vincristine; fludarabine; ibrutinib; metoprolol; obinutuzumab; rituximab; amiodarone; antiarrhythmic agent; ibrutinib; protein kinase inhibitor; pyrazole derivative; pyrimidine derivative, adult; Article; brain ischemia; cancer combination chemotherapy; cardioversion; case report; chronic lymphatic leukemia; clinical article; drug dose reduction; drug withdrawal; dyspnea; electrocardiogram; heart palpitation; human; loading drug dose; male; mantle cell lymphoma; middle aged; new-onset atrial fibrillation; priority journal; atrial fibrillation; chemically induced, Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines
DOI:
10.1177/1078155218785983
